Tibotec Pharmaceuticals' protease inhibitor darunavir [PREZISTA] has received conditional marketing authorisation from the European Commission

Source: Inpharma, Volume 1, Number 1576, 2007-02-24 , pp. 23-23(1)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: Darunavir, therapeutic use; Development-status; HIV-1-infections, treatment; Research-and-development; Tibotec-Pharmaceuticals

Document Type: Short communication

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$37.95 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A